Optimization of the therapeutic efficacy of human umbilical cord blood-mesenchymal stromal cells in an NSG mouse xenograft model of graft-versus-host disease

Cytotherapy

Volumn 16, Issue 3, 2014, Pages 298-308

  Jang, Yun Kyung ^a   Kim, Miyeon ^a   Lee, Young Ho ^b   Oh, Wonil ^a   Yang, Yoon Sun ^a   Choi, Soo Jin ^a  

^a MEDIPOST Co Ltd   (South Korea)

^b Hanyang University Medical Center   (South Korea)

Author keywords

Graft versus host disease; Human umbilical cord blood mesenchymal stromal cells; NSG mice; Therapeutic effect

Indexed keywords

GRAFT-VERSUS-HOST DISEASE; HUMAN UMBILICAL CORD BLOOD-MESENCHYMAL STROMAL CELLS; NSG MICE; THERAPEUTIC EFFECT;

ANIMALS; CELLS, CULTURED; DINOPROSTONE; DISEASE MODELS, ANIMAL; FETAL BLOOD; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED STRAINS; QUALITY IMPROVEMENT; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS;

EID: 84895090610     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.10.012     Document Type: Article

References (40)

1. Locatelli F., Rocha V., Chastang C., Arcese W., Michel G., Abecasis M., et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia: Eurocord-Cord Blood Transplant Group. Blood 1999, 93:3662-3671.
2. Bacigalupo A. Management of acute graft-versus-host disease. Br J Hematol 2007, 137:87-98.
3. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204-3213.
4. Goker H., Haznedaroglu I.C., Chao N.J. Acute graft-versus-host disease: pathobiology and management. Exp Hematol 2001, 29:259-277.
5. Iwasaki T. Recent advances in the treatment of graft-versus-host disease. Clin Med Res 2004, 2:243-252.
6. Ho V.T., Cutler C. Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol 2008, 21:223-237.
7. MacMillan M.L., Weisdorf D.J., Wagner J.E., DeFor T.E., Burns L.J., Ramsay N.K., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
8. Khoury H., Kashyap A., Adkins D.R., Brown R.A., Miller G., Vij R., et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001, 27:1059-1064.
9. Le Blanc K., Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:321-334.
10. Kebriaei P., Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 2011, 13:262-268.
11. Tolar J., Villeneuve P., Keating A. Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther 2011, 22:257-262.
12. Kuzmina L.A., Petinati N.A., Parovichnikova E.N., Lubimova L.S., Gribanova E.O., Gaponova T.V., et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease: a phase II study. Stem Cells Int 2012, 2012:968213. http://dx.doi.org/10.1155/2012/968213.
13. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific Tcells to their cognate peptide. Blood 2003, 101:3722-3729.
14. Maitra B., Szekely E., Gjini K., Laughlin M.J., Dennis J., Haynesworth S.E., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004, 33:597-604.
15. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
16. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
17. Tisato V., Naresh K., Girdlestone J., Navarrete C., Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007, 21:1992-1999.
18. Polchert D., Sobinsky J., Douglas G., Kidd M., Moadsiri A., Reina E., et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008, 38:1745-1755.
19. Joo S.Y., Cho K.A., Jung Y.J., Kim H.S., Park S.Y., Choi Y.B., et al. Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy 2010, 12:361-370.
20. Highfill S.L., Kelly R.M., O'Shaughnessy M.J., Zhou Q., Xia L., Panoskaltsis-Mortari A., et al. Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood 2009, 114:693-701.
21. Yang S.E., Ha C.W., Jung M., Jin H.J., Lee M., Song H., et al. Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy 2004, 6:476-486.
22. Cooke K.R., Kobzik L., Martin T.R., Brewer J., Delmonte J., Crawford J.M., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood 1996, 888:3230-3239.
23. Ito R., Katano I., Kawai K., Hirata H., Ogura T., Kamisako T., et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 2009, 87:1654-1658.
24. Min C.K., Kim B.G., Park G., Cho B., Oh I.H. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:637-645.
25. Gregoire-Gauthier J., Selleri S., Fontaine F., Dieng M.M., Patey N., Despars G., et al. Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graft-versus-host disease in a xenogenic mouse model. Stem Cells Dev 2012, 21:1616-1626.
26. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
27. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
28. Chen W., Li M., Li Z., Yan Z., Cheng H., Pan B., et al. CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease. Immunol Lett 2012, 143:161-169.
29. Noort W.A., Kruisselbrink A.B., in't Anker P.S., Kruger M., van Bezooijen R.L., de Paus R.A., et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 2002, 30:870-878.
30. Kraitchman D.L., Tatsumi M., Gilson W.D., Ishimori T., Kedziorek D., Walczak P., et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005, 112:1451-1461.
31. Yang X., Balakrishnan I., Torok-Storb B., Pillai M.M. Marrow stromal cell infusion rescues hematopoiesis in lethally irradiated mice despite rapid clearance after infusion. Adv Hematol 2012, 2012:142530. http://dx.doi.org/10.1155/2012/142530.
32. Tobin L.M., Healy M.E., English K., Mahon B.P. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol 2013, 172:333-348.
33. Bruck F., Belle L., Lechanteur C., de Leval L., Hannon M., Dubois S., et al. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy 2013, 15:267-279.
34. Wynn R.F., Hart C.A., Corradi-Perini C., O'Neill L., Evans C.A., Wraith J.E., et al. Asmall proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004, 104:2643-2645.
35. Piovan E., Tosello V., Indraccolo S., Masiero M., Persano L., Esposito G., et al. Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis. Cancer Res 2007, 67:8605-8614.
36. Schioppa T., Uranchimeg B., Saccani A., Biswas S.K., Doni A., Rapisarda A., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. JExp Med 2003, 198:1391-1402.
37. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858-864.
38. Wang X., Li C., Chen Y., Hao Y., Zhou W., Chen C., et al. Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. Biochem Biophys Res Commun 2008, 371:283-288.
39. Hung S.C., Pochampally R.R., Hsu S.C., Sanchez C., Chen S.C., Spees J., et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007, 2:e416.
40. Hu X., Dai S., Wu W.J., Tan W., Zhu X., Mu J., et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 2007, 116:654-663.